Zylacta

GAITHERSBURG, MD – August 10, 2009 – Zylacta Corporation, a biotechnology company developing products in viral diseases, CLD, and mesodermal cancers, today announced the issuance of Russian patent number 2363490 entitled "Biodegradable glucosaminemuramyl peptides for apoptosis modulation" covering the use of its eDD™ technology for producing glycopeptides of a broad therapeutic utility. The claims issued extend patent coverage for the eDD™ technology into 2023. "The Russian market represents a potential significant market opportunity for Zylacta," said Alex Dalsky, President & CEO of Zylacta. "eDD™ has demonstrated proof of concept of various efficacy with a broad spectrum of bacterial PGs. Going forward, the Company will look to partner the development of eDD™ with a group in Russia capable of bringing this technology to market in that region." About Zylacta Corporation Zylacta Corporation, a privately held company founded in 2004, is dedicated to developing genomic-driven solutions to producing novel immunotherapy medicines. The Company discovered that certain probiotic cell wall fragments represent important new classes of drugs, which the Company is well positioned to develop. The research team at Zylacta Corporation has invented a proprietary technology to generate a vast variety of natural glycopeptides from different types of bacterial PGN, allowing for the production of a class of novel compounds with broad therapeutic utility. For more information, visit www.zylacta.com.